Curis (CRIS) Net Income towards Common Stockholders (2010 - 2026)
Curis (CRIS) reported Net Income towards Common Stockholders of -$11.4 million for Q1 2026, down 7.78% on a YoY basis from -$12.4 million in Q1 2025, and down 159.11% quarter-over-quarter from $19.4 million in Q4 2025.
Curis (CRIS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Curis has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$11.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 7.78% year-over-year to -$11.4 million; the trailing twelve-month figure through Mar 2026 stood at -$8.4 million (up 80.04% YoY), and the FY2025 full-year result was -$7.6 million, up 82.53% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$11.4 million, down from $19.4 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $19.4 million in Q4 2025, with the low at -$16.1 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged -$9.8 million across 5 years, with a median of -$11.6 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 62.27% — and 2025, when it surged 301.25%.
- Curis' Net Income towards Common Stockholders stood at -$11.3 million in 2022, then declined by 3.38% to -$11.7 million in 2023, then grew by 17.88% to -$9.6 million in 2024, then surged by 301.25% to $19.4 million in 2025, then sank by 159.11% to -$11.4 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$11.4 million (Q1 2026), $19.4 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Curis | 8.27 Mn | -6.73 Mn | - | -11.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.44 Mn |
| Dec 31, 2025 | 19.36 Mn |
| Sep 30, 2025 | -7.73 Mn |
| Jun 30, 2025 | -8.59 Mn |
| Mar 31, 2025 | -10.62 Mn |
| Dec 31, 2024 | -9.62 Mn |
| Sep 30, 2024 | -10.09 Mn |
| Jun 30, 2024 | -11.80 Mn |
| Mar 31, 2024 | -11.88 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -12.18 Mn |
| Jun 30, 2023 | -11.96 Mn |
| Mar 31, 2023 | -11.56 Mn |
| Dec 31, 2022 | -11.33 Mn |
| Sep 30, 2022 | -13.29 Mn |
| Jun 30, 2022 | -15.94 Mn |
| Mar 31, 2022 | -16.11 Mn |
| Dec 31, 2021 | -13.62 Mn |
| Sep 30, 2021 | -11.05 Mn |
| Jun 30, 2021 | -11.73 Mn |